Race announces additional US Patent for Bisantrene
Released
Released
Announcement PDF
13 August 2019
ASX Announcement
Race announces additional US Patent for Bisantrene
13 August 2019: Race Oncology Limited (‘Race’) is pleased to announce that it has secured a new
patent on its cancer drug, Bisantrene, from the United States Patent and Trademarks Office (USPTO).
This is Race’s third patent granted on Bisantrene in the United States.
“The new US patent allows additional claims around the use of Bisantrene in combination with other
drugs for treating cancer,” said Race CEO Peter Molloy. “Given that most cancer treatments employ
combination regimens, we believe these new claims significantly bolster the attractiveness of
Bisantrene to commercial partners.”
The new patent covers expanded uses of Bisantrene, in particular its use in combination with other
cancer drugs to treat Acute Myeloid Leukaemia (AML) and breast cancer.
This includes the use of Bisantrene in combination with cytarabine, hypomethylating agents (for
example, azacitidine and decitabine), checkpoint inhibitors and other targeted immune therapies, as
well as other classes of cancer drugs.
The new patent is the result of a divisional application following on from one of the Race’s previous
Bisantrene patents granted in 2018 in the US (US9974774), which protected the use of Bisantrene in
patients with refractory or relapsed cancers, including AML and related leukaemias, as well as breast
cancer, lymphoma and other cancers. The latest patent expands Bisantrene’s protected use to
combination therapies.
-
ENDS
-
About Race Oncology (RAC: ASX)
Race Oncology is a specialty pharmaceutical company whose business model is to pursue later-stage
drug assets in the cancer field that have been overlooked by big pharma. The company’s first asset is
Bisantrene, a chemotherapy drug, which was the subject of more than 40 clinical studies during the
1980s and 1990s before the drug was abandoned. Bisantrene has compelling Phase II data in acute
myeloid leukaemia (AML) and Race is seeking to gain US FDA approval for Bisantrene for AML under
the accelerated 505(b)(2) regulatory pathway. Bisantrene is the subject of two recently granted US
patents and a third allowed US patent. It has also been awarded US Orphan Drug designation and a
‘Rare Paediatric Disease’ (RPD) designation.
Media contact:
Heidi Cuthbert, Multiplier
P: +61 411 272 366
E: heidi.cuthbert@multiplier.com.au
Race Oncology Ltd ABN 61 149 318 749
Registered office: L40, 140 William St, Melbourne VIC Australia 3000
www.raceoncology.com
Share your feedback
Discover